http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Late presentation of metastatic smooth muscle neoplasm of the uterus with low malignant potential
Gioia N. Canciani,Nikolaos Burbos,Timothy J. Duncan,Ray Lonsdale,Joaquin J. Nieto 대한부인종양학회 2012 Journal of Gynecologic Oncology Vol.23 No.1
A 48-year-old woman underwent total abdominal hysterectomy with conservation of the ovaries and tubes. Histology showed a well-circumscribed smooth muscle tumor with foci of degeneration (including infarct-type necrosis) but no coagulative tumor cell necrosis and only mild focal cytological atypia. She presented, 24 years later with shortness of breath and abdominal distension and underwent bilateral salpingo-oophorectomy, appendectomy, omental biopsy and para-aortic lymph node sampling. Histology showed bilateral ovarian smooth muscle tumors with no coagulative tumor cell necrosis or significant cellular atypia. The cells were mitotically active. The tumors in both ovaries were most likely secondary to the previous uterine smooth muscle neoplasm. To our knowledge, this case is the first in the literature to describe a benign cellular leiomyoma that subsequently behaved as a smooth muscle tumor of uncertain malignant potential, which recurred 24 years after the initial diagnosis.
Zucchi, Gioia,Khan, Jeffrey-A.,Vulfson, Evgeny-N. The Korean Society for Microbiology and Biotechnol 1998 Journal of microbiology and biotechnology Vol.8 No.6
The addition of decane to biotransfonnation media containing Yarrowia lipolytica led to the accumulation of intennediate L-phenylacetaldehyde and L-phenethyl acetate during bioconversion of L-phenylalanine, whilst none of these products were obtained in conventional aqueous fennentations. The results obtained support an earlier hypothesis (Spinnler et al. 1996. Proc. Natl. A cad. Sci. USA 93: 3373-3376) that organic solvents, acting as "thermodynamic traps" for hydrophobic intermediates, can substantially alter metabolic fluxes.
JPEG Pleno: Providing representation interoperability for holographic applications and devices
Peter Schelkens,Touradj Ebrahimi,Antonin Gilles,Patrick Gioia,오관정,Fernando Pereira,Cristian Perra,Antonio M. G. Pinheiro 한국전자통신연구원 2019 ETRI Journal Vol.41 No.1
Guaranteeing interoperability between devices and applications is the core role of standards organizations. Since its first JPEG standard in 1992, the Joint Photographic Experts Group (JPEG) has published several image coding standards that have been successful in a plethora of imaging markets. Recently, these markets have become subject to potentially disruptive innovations owing to the rise of new imaging modalities such as light fields, point clouds, and holography. These so‐called plenoptic modalities hold the promise of facilitating a more efficient and complete representation of 3D scenes when compared to classic 2D modalities. However, due to the heterogeneity of plenoptic products that will hit the market, serious interoperability concerns have arisen. In this paper, we particularly focus on the holographic modality and outline how the JPEG committee has addressed these tremendous challenges. We discuss the main use cases and provide a preliminary list of requirements. In addition, based on the discussion of real‐valued and complex data representations, we elaborate on potential coding technologies that range from approaches utilizing classical 2D coding technologies to holographic content‐aware coding solutions. Finally, we address the problem of visual quality assessment of holographic data covering both visual quality metrics and subjective assessment methodologies.
Alberto Mazza,Mariaceleste Nicoletti,Salvatore Lenti,Gioia Torin,Gianluca Rigatelli,Marzia Pellizzato,Andrea Fratter 한국식품영양과학회 2021 Journal of medicinal food Vol.24 No.1
The effectiveness of statins in the primary and secondary prevention of cardiovascular (CV) diseases has been widely proven. However, the onset of adverse events associated with their use prevents to achieve the therapeutic targets recommended by the guidelines (GL) for the management of dyslipidemia. In the event of statin intolerance, the GL recommend to use bile acid sequestrants, fibrates, and ezetimibe in monotherapy, but their benefits in improving lipid pattern are quite modest. This study aims at evaluating the effectiveness and safety of a nutraceutical compound (NC) associated with ezetimibe (EZE) on the lipid profile in statin-intolerant patients with moderate-to-high CV risk. Ninety-six statin-intolerant hypertensive and hypercholesterolemic subjects treated pharmacologically with EZE 10 mg daily were randomized in open label (n = 48) to take for 3 months a NC containing Monacolin-K (MK), Berberine Hydrochloride (BC), t-Resveratrol (RES), Quercetin (QUER), and Chromium (CH) in the form of a gastro-resistant tablet that improves enteric bioaccessibility and bioavailability of these substances. The control group (n = 48) took only EZE in monotherapy at the same dosage; both groups followed a standardized lipid-lowering diet. The total serum cholesterol (TC), low density lipoprotein cholesterol (LDLC), high density lipoprotein cholesterol (HDLC), triglycerides (TG), aspartate aminotransferase (AST), alanine aminotransferase (ALT), and creatinine phosphokinase (CPK) levels were compared at the follow-up in both groups using Student's t-test. TC and LDL levels reduced in both groups, but were lower in the group treated with EZE + NC (−25.9% vs. −15%, P < .05 and −38.7% vs. −21.0%, P < .05, respectively). No changes were observed in either group regarding a decrease in TG (−9.4% vs. −11.7%, NS) and an increase in HDLC (+4.2% vs. +1.1%, NS). The AST, ALT, and CPK levels increased in the group treated with the EZE + NC compared to the control group, but were still within the acceptable range. There was no difference concerning the lipid-lowering treatment between gender, and no patient withdrew from the study. In the short term, the EZE + NC combination therapy is well tolerated and effective in improving TC and LDLC levels in statin-intolerant patients with moderate-to-high CV risk.